Anti-mouse CD3e (Clone: 145-2C11) | Recombinant, in vivo grade

Catalog No.	Product Name	Size	List Price (US$)
PA007198.m2a	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa	1 mg	150.00
PA007198.m2a	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa	5 mg	350.00
PA007198.m2a	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa	25 mg	900.00
PA007198.h1	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Human IgG1 Kappa	1 mg	150.00
PA007198.h1	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Human IgG1 Kappa	5 mg	350.00
PA007198.h1	In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Human IgG1 Kappa	25 mg	900.00

Catalog No.

Product Name

Size

List Price (US$)

Quantity

PA007198.m2a

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa

1 mg

150.00

PA007198.m2a

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa

5 mg

350.00

PA007198.m2a

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa

25 mg

900.00

PA007198.h1

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Human IgG1 Kappa

1 mg

150.00

PA007198.h1

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Human IgG1 Kappa

5 mg

350.00

PA007198.h1

In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Human IgG1 Kappa

25 mg

900.00

Description

PA007198.m2a: In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa

Recombinant mouse IgG2a Monoclonal Antibody.
Clone: 145-2C11.
Isotype: Mouse IgG2a kappa.
Source: The anti-mouse CD3e monoclonal antibody (clone: 145-2C11) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 145-2C11) specifically binds to the mouse T cell receptor CD3e.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD3e protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions.

PA007198.h1: In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Human IgG1 Kappa

Recombinant human IgG1 Monoclonal Antibody.
Clone: 145-2C11.
Isotype: Human IgG1 Kappa.
Source: The anti-mouse CD3e monoclonal antibody (clone: 145-2C11) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant 145-2C11 antibody specifically binds to the mouse T cell receptor CD3e.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD3e protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11)

Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage

Shihyoung Kim, et al. Toxins (Basel). 2022 Jun 15;14(6):410. doi: 10.3390/toxins14060410. PMID: 35740248; PMCID: PMC9220018

"Targeted therapies using anti-CD3 epsilon monoclonal antibodies and immunotoxins represent promising strategies for managing various T-cell-related conditions. However, the use of immunotoxins is frequently associated with vascular leak syndrome, which presents significant clinical safety challenges. This investigation systematically compares the effects of CD3e-conjugated sZAP against the antibody alone, revealing that the sZAP component is primarily responsible for inducing vascular damage."

(Tags: 145-2C11; T cell activation)

CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells

Xingjie Ren, et al. Front Immunol. 2022 Oct 27;13:1012674. doi: 10.3389/fimmu.2022.1012674. PMID: 36389920; PMCID: PMC9643874

"Depleting T-cells remains a critical method for controlling immune-mediated pathologies, yet achieving selective depletion without destroying regulatory T-cell populations is difficult. This study demonstrates that CD3e-immunotoxins can effectively target high-expressing CD3e T-cells while leaving CD62L low-expressing regulatory T-cells intact. By selectively modulating the T-cell pool, this approach offers a refined method for reshaping organ-specific immune responses."

(Tags: In vivo depletion; CD3 depleting antibody)

The establishment and application of CD3E humanized mice in immunotherapy

Ying Wang, et al. Front Immunol. 2022 Oct 27;13:1013470. doi: 10.3389/fimmu.2022.1013470. PMID: 36415494; PMCID: PMC9671771

"Humanized mouse models are essential for translating preclinical immunotherapy findings into clinical success. The development of CD3E humanized mice has overcome previous limitations in testing anti-human CD3 therapies within immunocompetent environments. These models provide a robust framework for assessing the efficacy and safety of next-generation T-cell engagers and other CD3-targeting therapeutic agents."

(Tags: Mouse CD3e; Immunotherapy research)

Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3Ɛ humanized mice treated with polyclonal anti human thymocyte globulin

Maja Buszko, et al. PLoS One. 2017 Mar 3;12(3):e0173088. doi: 10.1371/journal.pone.0173088. PMID: 28257450; PMCID: PMC5336254

"Anti-thymocyte globulin (ATG) serves as a potent T-cell depleting agent widely used to mitigate rejection in allotransplant settings. Unlike earlier monoclonal anti-CD3 therapies, which caused broad depletion, ATG demonstrates a unique ability to eliminate circulating T-cells while preserving specific regulatory subsets. The use of CD3E humanized mouse models confirms that this differential depletion profile significantly enhances graft survival outcomes."

(Tags: 145-2C11; T cell signaling)

A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy

Paul S. Moore, et al. PLoS One. 2021 Feb 17;16(2):e0245917. doi: 10.1371/journal.pone.0245917. PMID: 33596227; PMCID: PMC7888618

"Translational research relies heavily on accurate preclinical models to bridge the gap between initial drug discovery and human clinical trials. This report details the creation of a novel genetic knock-in mouse strain expressing humanized CD3ε, which renders the model susceptible to therapeutic manipulation. Our results validate this humanized platform as a highly effective tool for preclinical assessment of anti-human CD3 antibodies."

(Tags: Anti-mouse CD3; T cell depletion)